Chronic Lymphocytic Leukemia — An Interview with Dr Lindsey Roeker on Key Presentations from the 66th American Society of Hematology (ASH) Annual Meeting

Featuring an interview with Dr Lindsey Roeker, including the following topics:

• Clinical development of novel Bruton tyrosine kinase (BTK) degraders in therapy for chronic lymphocytic leukemia (CLL) (0:00)
• Safety of BTK inhibitors in older and frail patients with CLL (3:41)
• Utility of minimal residual disease-guided treatment with venetoclax/obinutuzumab (9:20)
• Impact of the AMPLIFY study of acalabrutinib with venetoclax with or without obinutuzumab in CLL (16:32)
• Utility of acalabrutinib, venetoclax and obinutuzumab for high-risk CLL (23:31)
• Emerging data with sonrotoclax and zanubrutinib in treatment-naïve CLL (25:16)
• Sequencing, tolerability and future development involving pirtobrutinib (25:57)
• Emerging data with the addition of a BTK inhibitor to chimeric antigen receptor T-cell therapy (32:28)
• Clinical considerations in the management of Richter's transformation (38:14)
• Survival outcomes and quality of life for patients with CLL (41:02)
• Ongoing and future efforts to improve CLL treatment outcomes (45:01)

CME information and select publications